The U.S. Market and Developments Associated with Psoriasis

Countries covered: United States Special Offer: Now 25% off original sale price of $1995 Psoriasis has long been a dermatological problem that affects millions of people in the US. Current therapeutic approaches such as lubricants, keratolytic agents and topical corticosteroids have been used for decades. Advances in science offer the potential for actual curative therapy. This dedicated report from Kalorama Information examines the current and future market for therapeutic agents, including " Natural" approaches in the treatment of psoriasis. Product areas include: Current Products/methods Lubricants Keratolytics Topical Corticosteroids Antimetabolites Topical Retinoids UV Treatment Advanced/Developmental Approaches Antioxidents An array of monoclonal antibodies Cytokines PVAC Oral Retinoids Others Market size, segmentation and trends are presented and discussed.

Download a Flyer (Acrobat Reader required)

Additional Information

Scope and Methodology

This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options that they present, and the progress that is being made in these fields. The major market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to begin to be seen in the relatively short term, that is, within two to three years. The technology trends selected in conjunction with the growing interest in psoriasis and its treatment present the most informative picture of advances in psoriasis and psoriatic arthritis therapeutics and the markets that result.

This report covers current therapeutics, in a broad sense. It does not go into the detail of the dynamics of these various drugs in the marketplace, either branded (proprietary) or generic. The ability to do so is limited by several factors, including multiple on- and off-label applications for which it is not possible to discriminate among in the marketplace, and the mixture of branded and generic products used in psoriasis therapy. It does discuss, however, the impacts that advanced technologies and applications will have on existing therapeutics markets in the whole. In general, it is the current products and technologies used in the marketplace that have placed today’s market in a position that is vulnerable to psoriasis-specific technologies and products. Advanced psoriasis therapeutics will replace many of these products used to treat moderate-to-severe psoriasis and psoriatic arthritis. In an era of cost containment and managed care, however, the market value may be limited somewhat by existing standards. Moreover, the market for therapeutics to treat mild cases of psoriasis may continue to be primarily an OTC market, resistant to early entries by advanced therapeutics that require prescriptions.

Market analysis for this report considers the psoriasis and psoriatic arthritis therapeutics markets in the United States. This report does not consider instrumentation, such as UV-B and UV-A light sources and laser units, and their disposable support products. Some mention is made of therapeutic phototherapy and its related photosensitizers, but the specific market dynamics of that segment are not considered in detail. The focus of the report is on pharmaceutical-based technologies and products with the potential to become first-line therapies specifically for psoriasis and psoriatic arthritis, and does not consider in detail those products with secondary application to psoriasis or alternative therapy approaches.

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews, as well as interviews and discussions with experts in the field, including immunologists, dermatologists, rheumatologists, pathologists, research scientists, business development managers and marketing managers.

Press Release

“New Developments in the Psoriasis Therapeutics Create Market Opportunities ”

New York, June 29, 2001 /PR Newswire –- The advent of new biotechnology-derived innovations has re-energized the stagnant field of psoriasis therapeutics. According to a study released today by Kalorama Information, a division of MarketResearch.com, the current U.S. market for psoriasis therapeutics stands at $4.3 billion, but is expected to reach $6 billion by the year 2007,

The study, The U.S. Market and Developments Associated with Psoriasis, reviews current and pending approaches to psoriasis and psoriatic arthritis, particularly examining the progress being made in advanced therapeutics, such as antioxidants, monoclonal antibodies, cytokines, PVAC, and oral retinoids.

As outcomes focused on quality of life become more important in the healthcare system and researchers make advances in the understanding of the immune and inflammatory system, psoriasis will move from a “second string opportunity” to a legitimate and significant pharmaceutical prospect, according to the study. Although many patients with mild psoriasis will continue to self medicate and use over-the-counter preparations, this study clearly shows that they will likely move to the prescription sector as the disease begins to progress and new, more effective agents are made available and promoted.

“The psoriasis industry has historically been a highly fragmented one. In general, pharmaceutical companies have not wanted to be identified with psoriasis—a condition for which there is no known cause or cure,” notes Steven Heffner, Acquisitions Editor at Kalorama. “Pharmaceutical companies don’t want to be associated with products that don’t provide a solution to a problem.” However, the study reveals that a new interest in psoriasis has developed in young biotechnology and biopharmaceutical companies. These firms are developing therapeutics directed specifically at psoriasis and psoriatic arthritis, and in doing so they are creating an identifiable and promising industry of psoriasis therapeutics.

About Kalorama Information Kalorarma Information, a division of MarketResearch.com, supplies the latest in pharmaceutical research, exploring treatments and technology, legislation, regulation, and ideological trends. For more information, contact Steven Heffner, 212-807-2634 or sheffner@marketresearch.com.

About MarketResearch.com MarketResearch.com is the leading provider of global market intelligence products and services. With over 40,000 research publications from more than 350 top consulting and advisory firms, we offer instant online access to the world’s most extensive database of expert insights on global industries, companies, products, and trends. Updated daily. For more information, contact Kim Bolus at 212.807.2655 or kbolus@marketresearch.com, or visit www.MarketResearch.com.

Examine the Major Market Effects of the Latest Psoriasis Therapeutic Developments

New! The U.S. Market and Developments Associated with Psoriasis report, published by Kalorma Information is now available through MarketResearch.com. The available market of psoriasis therapeutics for the U.S. is surprisingly large with the available market growing from approximately $4.3 billion in 2001 to almost $6 billion in the year 2007.

This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options that they present, and the progress that is being made. Highlighted in this report are the major market effects of new therapeutics, technology trends, size and growth of the market, and competitive analysis.

Issues examined in this report include:

• Market size segmentation and trends
• Nature of the Industry
• Market Analysis
• Competitive Analysis

The U.S. Market and Developments Associated with Psoriasis provides an in-depth discussion of current therapies including such things as topical therapy, phototherapy, systemic medication, arthritic agents, palliative drugs, disease modifying agents, and alternative therapies. This report will help you to assess market size and dynamics, industry trends and give you the information you need to understand the changes that directly impact business performance, organizational issues and strategies.

This report is key to staying competitive; the U.S. Market and Developments Associated with Psoriasis includes an overview of some of the top companies that have psoriasis/psoriatic arthritis therapeutics in development, as well as an appendix with 180 company names and addresses in the U.S. and abroad with products associated with the psoriasis market. Learn what your competitors are doing and adjust your strategies to stay ahead.

Kalorama Information reports supply the latest in pharmaceutical and biotechnology research, exploring treatments and technology, legislation, regulation and ideological trends.

The U.S. Market and Developments Associated with Psoriasis report is available through MarketResearch.com, the leading provider of global market intelligence products and services.

With MarketResearch.com, you can purchase this report as a complete study, or buy discrete segments using the options below:

• MarketLooks – concise, graphic-rich summaries of full-length market research reports available for online delivery. These PDF files provide industry high points in an easy to read format.
• Buy By the Slice – a cost-effective option that enables you to select and purchase exactly what you value most.

Issues Addressed:

• Market size segmentation and trends
• Nature of the industry
• Competitive analysis
• Market forecast (1999-2007) for both available and serviceable markets
• Current therapeutic entities and utilization

Companies/Sites Discussed:

• Abgenix, Inc.
• Alexion Pharmaceuticals, Inc.
• Angiotech Pharmaceuticals, Inc.
• Biogen, Inc.
• Corixa Corp.
• Cypress Bioscience, Inc.
• Genetech, Inc.
• Genmad A/S
• IDEC Pharmaceuticals, Inc.
• Immunex, Inc.
• ISIS Pharmaceuticals
• Photogen Technologies, Inc.
• Vasogen, Inc.
• Xoma, Ltd.

Categories Covered:

• Background/prevalence of psoriasis and psoriatic arthritis
• Advanced/developmental approaches
• UVA/UVB treatment
• Current products/technologies in development aimed specifically at psoriasis

Tables and Graphs:

• Table 1-1 Prevalence of psoriatic arthritis in the United States
• Figure 1-1 Distribution of psoriasis cases by severity in the U.S.
• Table 1-2 Common psoriasis treatments
• Table 1-5 Companies with psoriasis/psoriatic arthritis therapeutics in development

More United States Dermatology Reports

Medicated Skin Care in the US by Euromonitor International
Medicated skin care continued to benefit from growing consumer demand in a variety of specialty/niche segments. Hair loss treatments, for example, continued to benefit from ...

U.S. Skin Cancer Market by Frost & Sullivan
This research service analyzes the U.S. skin cancer therapeutics market. Market drivers, restraints and challenges faced by industry participants are analyzed. Revenue forecasts for marketed ...

Freedonia Focus on Cosmetic Surgery Products by Freedonia Focus
This report discusses demand for cosmetic surgery products in the US for the years 2004 and 2009, with forecasts for 2014. Topics covered include ...

Cosmetic Surgery Products by Freedonia Group Inc
US demand to grow 6.5% annually through 2014 Demand for products used in cosmeticsurgery is forecast to increase 6.5 percentper year to $2.8 billion in 2014, ...

U.S. Market for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011 by iData Research, Inc.
The market for cosmetic surgery, facial aesthetics and medical laser devices is expected to almost double in size, exceeding $3 billion by 2017. The market ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>